Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2004-10-13
pubmed:abstractText
In this study, we analyzed the relationship between the plasma concentration of thalidomide and the therapeutic effect obtained by using thalidomide alone in patients with refractory multiple myeloma. The safety and effect of thalidomide was examined in 12 cases of refractory multiple myeloma. Four cases (33%) achieved partial response (PR) and 3 cases (25%) achieved minimal response. These effects were achieved with only 200 mg/day of thalidomide and maintained with 100-200 mg/day. The concentration of thalidomide in the blood was measured in 7 cases; dose-dependency was not recognized. In 5 cases in which complete or partial response was obtained, the effect was obtained with a mean thalidomide concentration in blood of 0.5 microg/mL or less. However, in 2 cases in which the mean blood concentration of thalidomide was 2 microg/mL or higher, an M-protein-reducing effect was not obtained. The frequency of various side effects was increased when the concentration of thalidomide was higher than 2 microg/mL. In conclusion, low-dose thalidomide therapy may effectively treat refractory myeloma, and the measurement of thalidomide concentration in the blood may not be a marker of therapeutic effect, but rather a marker of adverse effects.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1080-2924
pubmed:author
pubmed:issnType
Print
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
132-6
pubmed:dateRevised
2005-12-7
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Unstable plasma thalidomide concentration in patients with refractory multiple myeloma.
pubmed:affiliation
School of Health Sciences, Faculty of Medicine, Gunma University, Gunma 371-8511, Japan.
pubmed:publicationType
Journal Article